Community-acquired methicillin-resistant Staphylococcus aureus in bone and joint infections: development of rifampicin resistance

• 1 Department of Microbiology and Infectious Diseases, Liverpool Health Service, Sydney, NSW
• 3 Department of Microbiology and Infectious Diseases, South Western Area Pathology Service, Locked Bag 7090, Liverpool BC 1871, and Conjoint Associate Professor, School of Medical Sciences, University of New South Wales, Sydney, NSW.

---

• 1. Martinez-Aguilar G, Avalos-Mishaan A, Hulten K, et al. Community-acquired, methicillin-resistant and methicillin-susceptible Staphylococcus aureus musculoskeletal infections in children. Pediatr Infect Dis J 2004; 23: 701-706.
• 2. Ruhe JJ, Monson T, Bradsher RW, Menon A. Use of long-acting tetracyclines for methicillin-resistant Staphylococcus aureus infections: case series and review of the literature. Clin Infect Dis 2005; 40: 1429-1434.
• 3. Stein A, Bataille JF, Drancourt M, et al. Ambulatory treatment of multidrug-resistant Staphylococcus-infected orthopedic implants with high-dose oral cotrimoxazole (trimethoprim-sulfamethoxazole). Antimicrob Agents Chemother 1998; 42: 3086-3091.
• 4. Drinkovic D, Fuller ER, Shore KP, et al. Clindamycin treatment of Staphylococcus aureus expressing inducible clindamycin resistance. J Antimicrob Chemother 2001; 48: 315-316.
• 5. Munckhof WJ, Kleinschmidt SL, Turnidge JD. Resistance development in community-acquired strains of methicillin-resistant Staphylococcus aureus: an in vitro study. Int J Antimicrob Agents 2004; 24: 605-608.